Salvador Macip

3.6k citations
62 papers · 2.6k indexed · 1 hit paper · h-index 27

Salvador Macip

59 papers receiving 2.6k citations

Hit Papers

The BCL2 family: from apoptosis mechanisms to new advance...56202520261020304050

Peers

Salvador Macip
Comparison fields: 5 of 123
  • Aging 93
  • Cancer Research 365
  • Immunology 492
  • Molecular Biology 1.5k
  • Physiology 539
Replace Emanuela Grassilli with:
Emanuela Grassilli Italy
Liqin Wang China
Michael J. Ausserlechner Austria
Megan Cully United Kingdom
Shan Jiang China
Masood A. Shammas United States
Katarzyna Piwocka Poland
Ezgi Tasdemir France
Wei Zhuo China
Wenyong Chen United States
Salvador Macip relative to Emanuela Grassilli Italy Emanuela Grassilli's profile →
Citations per field
00.5×5.2×
Emanuela Grassilli · 1×
Citations per year

Countries citing papers authored by Salvador Macip

Since Specialization
Citations

This map shows the geographic impact of Salvador Macip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvador Macip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvador Macip more than expected).

Fields of papers citing papers by Salvador Macip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salvador Macip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvador Macip. The network helps show where Salvador Macip may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Salvador Macip, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Salvador Macip Line = papers co-authored together Salvador Macip links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20245
3 20241
4 20225
5 202137
6 202118
7 20205
8 202019
9 201933
10 201927
11 201821
12 201648
13 201642
14 20161
15 201332
16 2008193
17 200618
18 20053
19 2004206
20 2002303

About Salvador Macip

Salvador Macip is a scholar working on Genetics, Oncology and Hematology, having authored 62 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (14 papers), Chronic Lymphocytic Leukemia Research (12 papers), Telomeres, Telomerase, and Senescence (9 papers), Ubiquitin and proteasome pathways (7 papers), Advanced biosensing and bioanalysis techniques (7 papers), Cell death mechanisms and regulation (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and interferon and immune responses (5 papers). The work is most often cited by research in Aging (93 citations), Cancer Research (365 citations) and Immunology (492 citations). Salvador Macip has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Sam W. Lee, Stuart A. Aaronson, Mohammad Althubiti, Jian Yu, Makoto Igarashi, Petra Berggren, Miran Rada, George D.D. Jones, Marta Poblocka and Junji Sagara. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and The EMBO Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026